Home - Products - Others - Other Targets - DS-2330

DS-2330

CAS No. 1634680-81-1

DS-2330( DS2330 | DS-2330b )

Catalog No. M12462 CAS No. 1634680-81-1

DS-2330 is a phosphorous lowering agent for treating hyperphosphatemia in chronic kidney disease.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
100MG	Get Quote	Get Quote
200MG	Get Quote	Get Quote
500MG	Get Quote	Get Quote
1G	Get Quote	Get Quote

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

DS-2330
Note

Research use only, not for human use.
Brief Description

DS-2330 is a phosphorous lowering agent for treating hyperphosphatemia in chronic kidney disease.
Description

DS-2330 is a phosphorous lowering agent for treating hyperphosphatemia in chronic kidney disease.Other Indication Phase 1 Clinical.
In Vitro

——
In Vivo

——
Synonyms

DS2330 | DS-2330b
Pathway

Others
Target

Other Targets
Recptor

Other Targets
Research Area

Other Indications
Indication

Other Disease

Chemical Information

CAS Number

1634680-81-1
Formula Weight

780.937
Molecular Formula

C43H48N4O8S
Purity

>98% (HPLC)
Solubility

——
SMILES

——
Chemical Name

4-(4-(2-(3-(N-((1r,4r)-4-carboxycyclohexyl)-N-ethylsulfamoyl)benzamido)-5-(piperidin-1-yl)benzamido)phenethyl)benzoic acid

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

Sesamol

Sesamol could decrease lung inflammation and lipopolysaccharide (LPS)-induced lung injury in rats.
EMPA

EMPA is a selective, high-affinity and reversible antagonist of orexin OX2 receptor(human and rat OX2-HEK293 membranes with KD values of 1.1 and 1.4 nM respectively)EMPA displaces the EMPA binding from cell membranes containing human and rat OX2 receptors, with Ki values of 1.10±0.24 nM and 1.45±0.13 nM, respectively.?
Fezakinumab

Fezakinumab is a potent monoclonal antibody to interleukin-22 (IL-22). Fezakinumab can be used to study immune system diseases and inflammation-related conditions such as psoriasis, rheumatoid arthritis and atopic dermatitis.

Sign In Join Free